Prime Medicine, Inc.
PRME
$3.55
$0.3310.25%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -23.31% | -33.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -23.31% | -33.39% | |||
| Cost of Revenue | 12.68% | -91.63% | |||
| Gross Profit | -50.00% | 95.61% | |||
| SG&A Expenses | -1.26% | 7.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.20% | 16.03% | |||
| Operating Income | -1.88% | -18.47% | |||
| Income Before Tax | -1.35% | -22.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.35% | -22.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.35% | -22.74% | |||
| EBIT | -1.88% | -18.47% | |||
| EBITDA | -1.62% | -19.26% | |||
| EPS Basic | -2.67% | -22.79% | |||
| Normalized Basic EPS | -4.17% | -20.04% | |||
| EPS Diluted | -2.67% | -22.79% | |||
| Normalized Diluted EPS | -4.17% | -20.04% | |||
| Average Basic Shares Outstanding | -1.30% | -0.03% | |||
| Average Diluted Shares Outstanding | -1.30% | -0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||